Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on November 07, 2014, 01:44:14 pm
-
Janssen’s NS3/4A protease inhibitor Olysio and Gilead Sciences’ nucleotide analog NS5B polymerase inhibitor Sovaldi were each approved at the end of 2013 and since then have often been prescribed together.
But because Olysio and Sovaldi had not been approved as a combination therapy, clinicians have had to prescribe them off label. This approval removes that technicality.
Read more: http://www.hepmag.com/articles/Olysio_Sovaldi_approval_2501_26373.shtml